For as long as medicine has existed, cancers have ravaged humanity. The search for an eventual cure has been a tremendous & tireless pursuit, selflessly undertaken by doctors, researchers, scientists & the entire healthcare community. With each passing year and the availability of sophisticated technologies, their efforts continue to go from strength to strength, expanding our means to adequately cope, manage and possibly rebuff the disease which has so often reminded us of our mortality. Up until recently, Chemotherapy, Surgeries, Radiation & Targeted Drug therapies had been the go-to for…Read More
Tag: immune checkpoint Inhibitors
Discussing the latest IO developments at the 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021
July, 08th 2021 – 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021 to be held on the 26th-29th October 2021 will host top tier institutes pharmaceutical, bio-pharmaceutical and biotechnology companies like Scancell, Regeneron Pharmaceuticals, Cancer Vaccines Ltd, Boston Immune Technologies & Therapeutics & more to deliver the key challenges and future directions in IO research and to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors The conference aims to bring together 25+ industry thought leaders & 200+ attendees from pharmaceutical and…Read More
“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”- A brief discussion with Juan Perez Villar, CEO, LeadArtis.
Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid tumors at Leadartis. He advanced the company from start to capitalize on the immuno-oncology (IO) market. Evaluated and repositioned the platform technology to create IO bispecific antibody dominance and created a proprietary next generation product…Read More
Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”
Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic antibodies in murine models of human autoimmune diseases. After obtaining his Ph.D., he combined two postdoctoral grants in Barcelona (Metastasis and Transformation group in Bellvitge Biomedical Research Center) and in Valencia (Autoimmune Pathology Lab in…Read More
Dr. William Williams of Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer
Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into the clinic and established proof of concept in several disease areas. At GlaxoSmithKline he worked to bring several molecules into the clinic, ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug…Read More
What do MNM Analysts have to say about the Immuno Oncology Market?
Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC’s, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case…Read More